We have located links that may give you full text access.
E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced Melanoma.
Clinical Cancer Research 2018 November 13
PURPOSE: Interferon-α favors a Th1 shift in immunity and combining with ipilimumab (ipi) at 3 or 10 mg/kg may downregulate CTLA4-mediated suppressive effects leading to more durable antitumor immune responses. A study of tremelimumab and high-dose interferon-α (HDI) showed promising efficacy supporting this hypothesis.
EXPERIMENTAL DESIGN: E3611 followed a 2 by 2 factorial design (A: ipi10+HDI; B: ipi10; C: ipi3+HDI; D: ipi3) to evaluate (i) no HDI versus HDI (across ipi doses) and (ii) ipi3 versus ipi10 (across HDI status). We hypothesized that median progression free survival (PFS) would improve from 3 to 6 months with HDI versus no HDI and with ipi10 versus ipi3.
RESULTS: For eligible and treated patients (N=81) at a median follow-up time of 29.8 months, median PFS was 4.4 months (95%CI: 2.7-8.2) when ipilimumab was used alone and 7.5 months (95%CI: 5.1-11.0) when HDI was added. Median PFS was 3.8 months (95%CI: 2.6-7.5) with 3mg/kg ipilimumab and 6.5 months (95%CI: 5.1-13.5) with 10mg/kg. By study arm, median PFS was 8.0 months (95%CI: 2.8-20.2) in arm A, 6.2 months (95%CI: 2.7-25.7) in B, 5.7 months (95%CI: 1.5-11.1) in C and 2.8 months (95%CI: 2.6-5.7) in D. The differences in PFS and overall survival (OS) did not reach statistical significance. Adverse events were consistent with the known profiles of ipilimumab and HDI and significantly higher with HDI and ipi10.
CONCLUSIONS: While PFS was increased, the differences resulting from adding interferon-α or higher dose of ipilimumab did not reach statistical significance and do not outweigh the added toxicity risks.
EXPERIMENTAL DESIGN: E3611 followed a 2 by 2 factorial design (A: ipi10+HDI; B: ipi10; C: ipi3+HDI; D: ipi3) to evaluate (i) no HDI versus HDI (across ipi doses) and (ii) ipi3 versus ipi10 (across HDI status). We hypothesized that median progression free survival (PFS) would improve from 3 to 6 months with HDI versus no HDI and with ipi10 versus ipi3.
RESULTS: For eligible and treated patients (N=81) at a median follow-up time of 29.8 months, median PFS was 4.4 months (95%CI: 2.7-8.2) when ipilimumab was used alone and 7.5 months (95%CI: 5.1-11.0) when HDI was added. Median PFS was 3.8 months (95%CI: 2.6-7.5) with 3mg/kg ipilimumab and 6.5 months (95%CI: 5.1-13.5) with 10mg/kg. By study arm, median PFS was 8.0 months (95%CI: 2.8-20.2) in arm A, 6.2 months (95%CI: 2.7-25.7) in B, 5.7 months (95%CI: 1.5-11.1) in C and 2.8 months (95%CI: 2.6-5.7) in D. The differences in PFS and overall survival (OS) did not reach statistical significance. Adverse events were consistent with the known profiles of ipilimumab and HDI and significantly higher with HDI and ipi10.
CONCLUSIONS: While PFS was increased, the differences resulting from adding interferon-α or higher dose of ipilimumab did not reach statistical significance and do not outweigh the added toxicity risks.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app